Cardiovascular Agents

Multum Therapeutic Class Comparison, United States, 2023

Total Prescriptions in (2023)

Drug Name	Total Prescriptions (2023)	Percent Share
Lisinopril	76,055,040	15.5%
Amlodipine	68,743,650	14%
Metoprolol	59,547,256	12.2%
Losartan	56,174,735	11.5%
Hydrochlorothiazide	31,775,978	6.5%
Furosemide	19,138,347	3.9%
Carvedilol	16,566,782	3.4%
Spironolactone	12,777,046	2.6%
Hydrochlorothiazide; Lisinopril	10,986,814	2.2%
Hydrochlorothiazide; Losartan	9,882,018	2%
Propranolol	9,699,273	2%
Atenolol	9,235,306	1.9%
Clonidine	8,128,032	1.7%
Valsartan	7,983,441	1.6%
Olmesartan	7,175,746	1.5%
Diltiazem	6,562,727	1.3%
Hydralazine	6,327,003	1.3%
Hydrochlorothiazide; Triamterene	5,806,865	1.2%
Nifedipine	5,318,747	1.1%
Chlorthalidone	5,041,667	1%
Isosorbide	5,038,469	1%
Irbesartan	4,225,719	0.9%
Sildenafil	3,760,682	0.8%
Benazepril	2,965,136	0.6%
Verapamil	2,819,767	0.6%
Doxazosin	2,735,066	0.6%
Telmisartan	2,693,426	0.6%
Amlodipine; Benazepril	2,681,344	0.5%
Nebivolol	2,568,390	0.5%
Torsemide	2,545,175	0.5%
Enalapril	2,507,125	0.5%
Tadalafil	2,443,769	0.5%
Sacubitril; Valsartan	2,442,362	0.5%
Nitroglycerin	2,238,377	0.5%
Ramipril	2,148,134	0.4%
Terazosin	1,989,756	0.4%
Amiodarone	1,974,862	0.4%
Bisoprolol	1,816,701	0.4%
Flecainide	1,805,937	0.4%
Labetalol	1,555,592	0.3%
Bumetanide	1,419,205	0.3%
Epinephrine	1,248,426	0.3%
Guanfacine	1,039,055	0.2%

Total Prescriptions by Drug Over Time

Drug Class Prescribing Trends Over Time

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2014-2023. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 2025.08. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).

Search

Mailing List

Get Email Updates

New and Popular

Open Menu

Cite This Page

Show AMA citation

Biostatistics Rx - Medical literature evaluation and biostats WITHOUT the complex math and formulas

Disclaimer - Privacy Policy - Contact Us
Updated Sep 12, 2021

Top